Aliskiren accumulation in the kidney: No major role for binding to renin or prorenin

Journal of Hypertension

Volumn 31, Issue 4, 2013, Pages 713-719

  Lange, Sascha ^a   Fraune, Christoph ^a   Alenina, Natalia ^b   Bader, Michael ^b   Danser, A H Jan ^c   Frenay, Anne Roos ^d   Van Goor, Harry ^d   Stahl, Rolf ^a   Nguyen, Genevieve ^e   Schwedhelm, Edzard ^a   Wenzel, Ulrich Otto ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Internal Medicine ^*

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Centre de Recherche Interdisciplinaire en Biologie   (France)

Author keywords

(P)RR; (pro)renin receptor; ACE; Ang; angiotensin; angiotensin II type 1 receptor; angiotensin receptor blocker; angiotensin converting enzyme; ARB; AT1a receptor; RAS; renin angiotensin system

Indexed keywords

ALISKIREN; ANGIOTENSIN 1A RECEPTOR; PEPTIDE; PRORENIN; RENIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE KIDNEY FUNCTION RELATION; DRUG ACCUMULATION; DRUG BINDING; DRUG EFFECT; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; WILD TYPE;

EID: 84875213364     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835e226b     Document Type: Article

References (30)

1. Rakusan D, Kujal P, Kramer HJ, Huskova Z, Vanourkova Z, Vernerova Z, et al. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol 2010; 299:F758-F766.
2. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24:93-103.
3. Du?sing R, Brunel P, Baek I, Baschiera F. Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study. J Hypertens 2012; 30:1029- 1040.
4. Fraune C, Lange S, Krebs C, Holzel A, Baucke J, Divac N, et al. AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease. Am J Physiol Renal Physiol 2012; 303:F1037-F1048.
5. McMurray JJ, Abraham WT, Dickstein K, Kober L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012; 14:341-343.
6. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213.
7. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52:130-136.
8. Batenburg WW, de Bruin RJ, van Gool JM, Muller DN, Bader M, Nguyen G, et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28:1151-1157.
9. Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005; 46:1069-1076.
10. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69:105-113.
11. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17:1950-1961.
12. Nabi A, Biswas K, Nakagawa T, Ichihara A, Inagami T, Suzuki F. 'Decoy peptide' region (RIFLKRMPSI) of prorenin prosegment plays a crucial role in prorenin binding to the (pro)renin receptor. Int J Mol Med 2009; 24:83-89.
13. Nabi A, Biswas K, Nakagawa T, Ichihara A, Inagami T, Suzuki F. Prorenin has high affinity multiple binding sites for (pro)renin receptor. Biochim Biophys Acta 2009; 1794:1838-1847.
14. Krop M, van Gool JM, Day D, Hollenberg NK, Danser AHJ. Evaluation of a direct prorenin assay making use of a monoclonal antibody directed against residues 32-39 of the prosegment. J Hypertens 2011; 29:2138-2146.
15. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci U S A 1995; 92:3521-3525.
16. Takahashi N, Lopez ML, Cowhig JE Jr, Taylor MA, Hatada T, Riggs E, et al. Ren1c homozygous null mice are hypotensive and polyuric, but heterozygotes are indistinguishable from wild-type. J Am Soc Nephrol 2005; 16:125-132.
17. van Esch JH, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AH. Handle region peptide counteracts the beneficial effects of the Renin inhibitor aliskiren in spontaneously hypertensive rats. Hypertension 2011; 57:852-858.
18. Krebs C, Fraune C, Schmidt-Haupt R, Turner JE, Panzer U, Quang MN, et al. CCR5 Deficiency Does Not Reduce Hypertensive End-Organ Damage in Mice. Am J Hypertens 2012; 25:479-486.
19. Krebs C, Hamming I, Sadaghiani S, Steinmetz OM, Meyer-Schwesinger C, Fehr S, et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 2007; 72:725-730.
20. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004; 47:5995-6008.
21. Prieto MC, Gonzalez AA, Navar LG. Evolving concepts on regulation and function of renin in distal nephron. Pflugers Arch 2012. [Epub ahead of print]
22. van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, Feelders RA, et al. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney. J Hypertens 2011; 29:2147-2155.
23. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370:221- 229.
24. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, et al. Renin inatherosclerosis in mice. J Clin Invest 2008; 118:984-993.
25. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308:698-705.
26. Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, et al. Aliskiren accumulates in Renin secretory granules and binds plasma prorenin. Hypertension 2008; 52:1076-1083.
27. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007; 35:1418-1428.
28. Tapaninen T, Neuvonen PJ, Niemi M. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol 2011; 71:718-726.
29. Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 2008; 74:320-329.
30. Nguyen G. Renin, (pro)renin and receptor: an update. Clin Sci (Lond) 2011; 120:169-178.